scholarly journals Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000

Cancer ◽  
2018 ◽  
Vol 124 (12) ◽  
pp. 2534-2540 ◽  
Author(s):  
Hagop M. Kantarjian ◽  
Courtney D. DiNardo ◽  
Graciela M. Nogueras-Gonzalez ◽  
Tapan M. Kadia ◽  
Elias Jabbour ◽  
...  
Keyword(s):  
Salvage Therapy ◽  
Acute Myelogenous Leukemia ◽  
Myelogenous Leukemia ◽  
Single Institution ◽  
Acute Myelogenous

Response to salvage therapy and survival after relapse in acute myelogenous leukemia.

1989 ◽  
Vol 7 (8) ◽  
pp. 1071-1080 ◽  
Author(s):  
M J Keating ◽  
H Kantarjian ◽  
T L Smith ◽  
E Estey ◽  
R Walters ◽  
...  
Keyword(s):  
Salvage Therapy ◽  
Acute Myelogenous Leukemia ◽  
Specific Treatment ◽  
Lactic Dehydrogenase ◽  
Myelogenous Leukemia ◽  
High Dose ◽  
Salvage Regimen ◽  
Conventional Dose ◽  
Acute Myelogenous ◽  
Probability Of Response

The response to and survival following first salvage therapy regimens for 243 patients with acute myelogenous leukemia (AML) treated between 1974 and 1985 were evaluated. Eighty (33%) patients obtained a complete remission (CR), 24% died prior to achieving a response, and 43% were resistant on their first salvage regimen. The median survival was 18 weeks. Five percent overall and 16% of the CR patients are predicted to survive for more than 5 years. The factor most strongly associated with response and survival was the duration of the initial remission with 49 of 82 (60%) patients whose initial CR duration was at least 1 year in duration obtaining a second CR v 31 of 161 (19%) for patients with a shorter remission (P less than .01). Age, liver function, serum lactic dehydrogenase (LDH), karyotype, and the proportion of blasts plus promyelocytes present at the time of starting salvage therapy were strongly associated with probability of response and survival. Multivariate analysis was used to develop logistic regression and proportional hazard models to predict probability of response and survival, respectively. The major regimens used were conventional-dose cytarabine (ara-C) (combined with anthracyclines or amsacrine), high-dose ara-C, rubidazone, amsacrine (AMSA), other anthracyclines, and autologous or allogeneic transplant programs. After allowing for the prognostic factors in the models, specific treatment regimens were not strongly associated with prognosis.

Outcome of First Salvage Therapy in Core Binding Factor Associated Acute Myelogenous Leukemia Is Less Than Optimal

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 2952-2952
Author(s):  
Carmen Fava ◽  
Deborah Blamble ◽  
Susan O’Brien ◽  
Guillermo Garcia-Manero ◽  
Sherry Pierce ◽  
...  
Keyword(s):  
Stem Cell ◽  
Salvage Therapy ◽  
Acute Myelogenous Leukemia ◽  
Stem Cell Transplant ◽  
Myelogenous Leukemia ◽  
Cell Transplant ◽  
Allogeneic Stem Cell Transplant ◽  
Core Binding Factor ◽  
Binding Factor ◽  
Acute Myelogenous

Abstract Background: Core binding factor (CBF) associated acute myelogenous leukemia (AML) is considered to have a better prognosis compared to that of other patients with AML. Reinduction with cytarabine based therapy followed by allogeneic stem cell transplant is a standard salvage approach. Method: We performed a retrospective analysis of outcome in patients with CBF AML. Results: Between the years 1992 and 2005, 107 patients with CBF AML were treated at M.D. Anderson Cancer Center. Sixty-six (62%) patients had inv 16 abnormality and 41 (38%) had t(8;21) abnormality. Induction chemotherapy regimens included fludarabine and cytarabine with or without granulocyte colony stimulating factor (G-CSF) (66 patients) or idarubicin and cytarabine with/without G-CSF (41 patients). One hundred and one (94%) patients achieved complete remission (CR). After a median CR duration of 159 weeks, 37 (37%) patients relapsed. Relapse rate was 26/66 (39%) among patients with inv 16 abnormality and 11/41 (27%) among those with t (8;21) abnormality. Higher WBC count predicted for relapse (p=.001) and relapse rate did not differ among induction regimens (p=0.1). Salvage chemotherapy included cytarabine based regimen in 22 (59%) patients, clofarabine and idarubicin (2 patients), topoisomerase inhibitor (5 patients), histone deacetylase inhibitor (2 patients) and miscellaneous regimens (6 patients). Sixteen (43%) of the patients with relapsed CBF AML achieved CR after first salvage therapy. Eleven of 26 (42%) patients with inv 16 and 7/11 (64%) of patients with t (8;21) were resistant to first salvage therapy. Thirteen patients (10 in CR) underwent allogeneic stem cell transplant and 12 of them remained in CR post-transplant. Overall survival was significantly worse among patients who relapsed compared to the ones who did not (p=.001). Conclusion: A significant proportion of patients with CBF AML relapse and second remissions can be achieved in less than half the patients. This highlights the need for better induction/consolidation regimens in this group of patients with ‘good-risk’ AML.

Effect of Complete Remission on Survival in Patients With Acute Myelogenous Leukemia Receiving First Salvage Therapy

Blood ◽  
1999 ◽  
Vol 93 (9) ◽  
pp. 3149-3150 ◽  
Author(s):  
Norbert Vey ◽  
Michael Keating ◽  
Francis Giles ◽  
Jorge Cortes ◽  
Miloslav Beran ◽  
...  
Keyword(s):  
Complete Remission ◽  
Salvage Therapy ◽  
Acute Myelogenous Leukemia ◽  
Myelogenous Leukemia ◽  
Acute Myelogenous

Risk factors for bacteremia and central line-associated blood stream infections in children with acute myelogenous leukemia: A single-institution report

2016 ◽  
Vol 64 (3) ◽  
pp. e26254 ◽  
Author(s):  
Ashley E. J. Rogers ◽  
Kristen M. Eisenman ◽  
Susan A. Dolan ◽  
Kristin M. Belderson ◽  
Jocelyn R. Zauche ◽  
...  
Keyword(s):  
Risk Factors ◽  
Acute Myelogenous Leukemia ◽  
Blood Stream ◽  
Central Line ◽  
Myelogenous Leukemia ◽  
Single Institution ◽  
Blood Stream Infections ◽  
Acute Myelogenous

Effect of Complete Remission on Survival in Patients With Acute Myelogenous Leukemia Receiving First Salvage Therapy

Blood ◽  
1999 ◽  
Vol 93 (9) ◽  
pp. 3149-3150 ◽  
Author(s):  
Norbert Vey ◽  
Michael Keating ◽  
Francis Giles ◽  
Jorge Cortes ◽  
Miloslav Beran ◽  
...  
Keyword(s):  
Complete Remission ◽  
Salvage Therapy ◽  
Acute Myelogenous Leukemia ◽  
Myelogenous Leukemia ◽  
Acute Myelogenous
Sign in / Sign up

Export Citation Format

Share Document